Overview of Gynomax
| Quick Facts | Description |
|---|---|
| Active Ingredients | Tinidazole, Tioconazole |
| Form | Vaginal Ovule (Pessary) |
| Pharmacological Class | Antiprotozoal/Antifungal Combination |
| Common Use | Mixed Vaginal Infections |
| Origin | Synthetic |
Gynomax is defined as a synthetic fixed-dose combination (FDC) product administered locally to address vaginal infections. It is classified as a broad-spectrum antimicrobial combination, comprising two primary agents: Tinidazole, an antiprotozoal agent and antibacterial compound, and Tioconazole, an Imidazole antifungal. This classification is used because the medicine is engineered to target diverse microbial classes simultaneously.
Composition and Delivery Form
The pharmaceutical identity of Gynomax is established by its two active ingredients. Tinidazole is a nitroimidazole derivative known for its activity against certain protozoa and anaerobic bacteria, while Tioconazole targets various fungi and yeasts. The medicine is delivered as a vaginal ovule, which is a solid or semi-solid form designed for intravaginal administration. This dosage form ensures the active components are concentrated locally where the microbial overgrowth is occurring, which is the key to its general therapeutic purpose.
Dual Action and Therapeutic Scope
The general therapeutic purpose of Gynomax is to address infections stemming from the concurrent presence of bacteria, parasites, and fungi. The combination of Tioconazole and an antiprotozoal agent simplifies treatment by enabling a single product to manage both fungal and protozoal components. This dual-action composition differentiates Gynomax from many single-agent therapies; it is inherently equipped to handle polymicrobial conditions—where fungal and bacterial imbalances may coexist—offering a consolidated therapeutic approach compared to single-component drugs that target only one microbial cause.
